No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CGEN Compugen
- 1.9000
- +0.0200+1.06%
Close Apr 19 16:00 ET
170.11MMarket Cap-9047P/E (TTM)
1.9700High1.8350Low325.37KVolume1.9100Open1.8800Pre Close615.93KTurnover0.38%Turnover RatioLossP/E (Static)89.53MShares3.030152wk High2.60P/B160.92MFloat Cap0.530052wk Low--Dividend TTM84.69MShs Float19.9000Historical High--Div YieldTTM7.18%Amplitude0.3400Historical Low1.8930Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Compugen Reports Publication Of Paper In Cancer Immunology Research Demonstrating Therapeutic Potential Of COM503
Compugen to Participate in Two Upcoming Investor Conferences
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Truist Financial Reaffirms Their Buy Rating on Compugen (CGEN)
Are You Looking for a Top Momentum Pick? Why Compugen (CGEN) Is a Great Choice
Compugen Selected for Two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
Compugen Is Maintained at Buy by Truist Securities
Compugen Is Maintained at Buy by Truist Securities
Comments
The market anticipates a decline in future revenue, possibly explaining the suppressed P/S. This weak revenue outlook could continue to pressure shares, making it hard to maintain current prices. Shareholders accept the low P/S, expecting future revenue may not bring pleasant surprises.
$Compugen(CGEN.US$ fk entered very early! now no option to hold at lesast 2 week or more !
$Compugen(CGEN.US$ 👀looks good i n game 🎲
Michelle Mahler's appointment as Chief Medical Officer is a positive step for Compugen, thanks to her vast clinical development experience. Her leadership in the COM503 Phase 1 study and future role in advancing COM701, COM902, and COM503 are anticipated to significantly boost the company's clinical development strategy.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg